Education
About Us
Working with TipRanks
Follow Us
PTC Therapeutics (DE:BH3)
FRANKFURT:BH3
Total Valuation
PTC Therapeutics has a market cap or net worth of $3.26B. The enterprise value is ―.
Market Cap$3.26B
Enterprise Value―
Share Statistics
PTC Therapeutics has 79,257,020 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding79,257,020
Owned by Insiders1.32%
Owned by Institutions0.94%
Financial Efficiency
PTC Therapeutics’s return on equity (ROE) is 0.33 and return on invested capital (ROIC) is -26.31%.
Return on Equity (ROE)0.33
Return on Assets (ROA)-0.21
Return on Invested Capital (ROIC)-26.31%
Return on Capital Employed (ROCE)-0.27
Revenue Per Employee859.19K
Profits Per Employee-386.90K
Employee Count939
Asset Turnover0.47
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of PTC Therapeutics is -9.55. PTC Therapeutics’s PEG ratio is -0.57.
PE Ratio-9.55
PS Ratio0.00
PB Ratio-3.80
Price to Fair Value-3.16
Price to FCF-36.59
Price to Operating Cash Flow-38.71
PEG Ratio-0.57
Income Statement
In the last 12 months, PTC Therapeutics had revenue of 806.78M and earned -363.30M in profits. Earnings per share was -4.73.
Revenue806.78M
Gross Profit806.78M
Operating Income-302.57M
Pretax Income-363.12M
Net Income-363.30M
EBITDA-120.46M
Earnings Per Share (EPS)-4.73
Cash Flow
In the last 12 months, operating cash flow was -107.69M and capital expenditures -9.23M, giving a free cash flow of -116.92M billion.
Operating Cash Flow-107.69M
Free Cash Flow-116.92M
Free Cash Flow per Share-1.48
Dividends & Yields
PTC Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.21
52-Week Price Change43.66%
50-Day Moving Average44.73
200-Day Moving Average39.73
Relative Strength Index (RSI)43.18
Average Volume (3m)5.00
Important Dates
PTC Therapeutics upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.
Last Earnings DateMay 6, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend Date―
Financial Position
PTC Therapeutics as a current ratio of 2.35, with Debt / Equity ratio of -225.04%
Current Ratio2.35
Quick Ratio2.31
Debt to Market Cap0.11
Net Debt to EBITDA3.24
Interest Coverage Ratio-1.81
Taxes
In the past 12 months, PTC Therapeutics has paid 176.00K in taxes.
Income Tax176.00K
Effective Tax Rate>-0.01
Enterprise Valuation
PTC Therapeutics EV to EBITDA ratio is -25.55, with an EV/FCF ratio of -26.96.
EV to Sales3.82
EV to EBITDA-25.55
EV to Free Cash Flow-26.96
EV to Operating Cash Flow-28.59
Balance Sheet
PTC Therapeutics has $1.14B in cash and marketable securities with $2.47B in debt, giving a net cash position of $1.33B billion.
Cash & Marketable Securities$1.14B
Total Debt$2.47B
Net Cash$1.33B
Net Cash Per Share$16.80
Tangible Book Value Per Share-$16.91
Margins
Gross margin is 86.14%, with operating margin of -37.50%, and net profit margin of -45.03%.
Gross Margin86.14%
Operating Margin-37.50%
Pretax Margin-45.01%
Net Profit Margin-45.03%
EBITDA Margin-14.93%
EBIT Margin-24.31%
Analyst Forecast
The average price target for PTC Therapeutics is $55.94, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$55.94
Price Target Upside40.54% Upside
Analyst ConsensusModerate Buy
Analyst Count13
Revenue Growth Forecast―
EPS Growth Forecast―